BioCentury | Nov 4, 2013
Strategy

Teva blinks

...2004-08: Teva senior management, including EVP, global pharmaceutical resources Chaim Hurvitz 2010-present Israel Director at Aposense Ltd....
BioCentury | Apr 11, 2011
Company News

Aposense, University of Pittsburgh deal

...The university received a license to use Aposense's EarliTest imaging technology in a NIH-funded clinical trial...
...LSE:GSK; NYSE:GSK) have licenses to use the EarliTest technology in clinical trials testing cancer compounds. Aposense Ltd....
BioCentury | Nov 15, 2010
Company News

Aposense, Roche deal

...Roche received a non-exclusive license to use Aposense's EarliTest technology in Roche's oncology development. Roche will...
...and pay Aposense undisclosed license fees. Aposense also is eligible to receive undisclosed milestone payments. Aposense Ltd....
BioCentury | Jul 5, 2010
Finance

3Q Financial Markets Preview: Summer scrapes bottom

...Date Raised Post-$ 6/30 mcap % chg IntegraGen S.A. (Euronext:ALINT) 6/16/10 $8.1 $38.4 $41.5 8% Aposense Ltd....
BioCentury | Jun 21, 2010
Company News

Aposense, Teva deal

...$9 million in its September 2005 deal with Aposense to co-develop therapeutics comprised of an Aposense...
...in preclinical testing. Aposense previously received a $2 million investment from Teva under the deal. Aposense Ltd....
BioCentury | Jun 14, 2010
Finance

IPO watch

...IPO watch Israeli molecular imaging and apoptosis play Aposense Ltd. (Tel Aviv:APOS) raised NIS95.9 million ($24.8 million...
...TEVA). Aposense has a 2006 deal with Teva to co-develop anti-cancer candidates comprised of an Aposense...
...up to an additional $9 million in the collaboration; the original terms haven't been undisclosed. Aposense's...
BioCentury | Jun 14, 2010
Financial News

Aposense completes IPO

Aposense Ltd. (Tel Aviv:APOS), Petach-Tikva, Israel Business: Cancer, Drug delivery, Diagnostic Date completed: 6/7/10 Type: IPO Raised: NIS95.9 million ($24.8 million) Shares: 3 million Price: NIS31.50 Shares after offering: 26.5 million Note: The offering included...
BioCentury | Jun 8, 2010
Financial News

Aposense prices IPO

...Meitav were agents in the offering. The first day of trading is slated for Wednesday. Aposense's...
BioCentury | Sep 28, 2009
Company News

Aposense, Ion Beam Applications deal

...2008 deal, giving Ion exclusive, worldwide rights to co-develop and co-commercialize the radiolabeled formulation of Aposense's...
...with Aposense to radiolabel and distribute the small molecules for use in Aposense's clinical trials. Aposense Ltd....
BioCentury | Jun 29, 2009
Clinical News

[18F]-ML-10: Phase II data

...effect of radiotherapy. Data were presented at the Society of Nuclear Medicine meeting in Toronto. Aposense Ltd....
Items per page:
1 - 10 of 14
BioCentury | Nov 4, 2013
Strategy

Teva blinks

...2004-08: Teva senior management, including EVP, global pharmaceutical resources Chaim Hurvitz 2010-present Israel Director at Aposense Ltd....
BioCentury | Apr 11, 2011
Company News

Aposense, University of Pittsburgh deal

...The university received a license to use Aposense's EarliTest imaging technology in a NIH-funded clinical trial...
...LSE:GSK; NYSE:GSK) have licenses to use the EarliTest technology in clinical trials testing cancer compounds. Aposense Ltd....
BioCentury | Nov 15, 2010
Company News

Aposense, Roche deal

...Roche received a non-exclusive license to use Aposense's EarliTest technology in Roche's oncology development. Roche will...
...and pay Aposense undisclosed license fees. Aposense also is eligible to receive undisclosed milestone payments. Aposense Ltd....
BioCentury | Jul 5, 2010
Finance

3Q Financial Markets Preview: Summer scrapes bottom

...Date Raised Post-$ 6/30 mcap % chg IntegraGen S.A. (Euronext:ALINT) 6/16/10 $8.1 $38.4 $41.5 8% Aposense Ltd....
BioCentury | Jun 21, 2010
Company News

Aposense, Teva deal

...$9 million in its September 2005 deal with Aposense to co-develop therapeutics comprised of an Aposense...
...in preclinical testing. Aposense previously received a $2 million investment from Teva under the deal. Aposense Ltd....
BioCentury | Jun 14, 2010
Finance

IPO watch

...IPO watch Israeli molecular imaging and apoptosis play Aposense Ltd. (Tel Aviv:APOS) raised NIS95.9 million ($24.8 million...
...TEVA). Aposense has a 2006 deal with Teva to co-develop anti-cancer candidates comprised of an Aposense...
...up to an additional $9 million in the collaboration; the original terms haven't been undisclosed. Aposense's...
BioCentury | Jun 14, 2010
Financial News

Aposense completes IPO

Aposense Ltd. (Tel Aviv:APOS), Petach-Tikva, Israel Business: Cancer, Drug delivery, Diagnostic Date completed: 6/7/10 Type: IPO Raised: NIS95.9 million ($24.8 million) Shares: 3 million Price: NIS31.50 Shares after offering: 26.5 million Note: The offering included...
BioCentury | Jun 8, 2010
Financial News

Aposense prices IPO

...Meitav were agents in the offering. The first day of trading is slated for Wednesday. Aposense's...
BioCentury | Sep 28, 2009
Company News

Aposense, Ion Beam Applications deal

...2008 deal, giving Ion exclusive, worldwide rights to co-develop and co-commercialize the radiolabeled formulation of Aposense's...
...with Aposense to radiolabel and distribute the small molecules for use in Aposense's clinical trials. Aposense Ltd....
BioCentury | Jun 29, 2009
Clinical News

[18F]-ML-10: Phase II data

...effect of radiotherapy. Data were presented at the Society of Nuclear Medicine meeting in Toronto. Aposense Ltd....
Items per page:
1 - 10 of 14